ZIF-8

ZIF-8 nanoparticles (0-24 h) remain stable in neutral pH (7.4) PBS but degrade and release ~53% of zinc ions within 24 h in acidic pH (6.5) PBS^[1].
ZIF-8 nanoparticles induce significant intracellular ROS generation in 4T1 mouse breast cancer cells^[1].
ZIF-8 nanoparticles induce significant intracellular zinc ion accumulation in 4T1 mouse breast cancer cells^[1].
ZIF-8 nanoparticles (25-50 μg/mL) exert concentration-dependent cytotoxicity against 4T1 mouse breast cancer cells, with an IC₅₀ of 23.1 μg/mL^[1].
ZIF-8 nanoparticles induce apoptosis and 31.4% necrosis in 4T1 mouse breast cancer cells^[1].
ZIF-8 nanoparticles (24 h) induce pyroptotic morphological changes and mitochondrial damage in 4T1 mouse breast cancer cells after 24 h of treatment^[1].
ZIF-8 nanoparticles upregulate cleaved caspase-1 and GSDMD expression to activate the caspase-1/GSDMD-dependent pyroptosis pathway in 4T1 mouse breast cancer cells^[1].
ZIF-8 nanoparticles induce significant release of pyroptosis markers LDH and IL-1β from 4T1 mouse breast cancer cells^[1].
ZIF-8-based carriers exhibit broad-spectrum pH-responsive drug release properties, effectively inhibiting drug leakage in physiologically neutral environments and significantly accelerating the release of loaded drugs such as DOX, CPT, arsenic, PHY, CIP, and fluorescein in acidic microenvironments, demonstrating excellent pH-dependent drug release performance^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.